<i>-HCV:</i><i>New Drug Application planned for telaprevir in second
half of 2010, robust commercialization and launch preparedness
activities ongoing-</i><br /><i>-CF:</i><i>Advancing development efforts in orphan disease of cystic
fibrosis; Phase 3 STRIVE trial with VX-770 completes planned enrollment,
VX-809 Phase 2 data expected in first quarter 2010-</i><br /><i>-Pipeline:</i><i>Proof-of-concept clinical trials planned for 2010
with novel combination regimens for hepatitis C and cystic fibrosis and
with compounds for rheumatoid arthritis and epilepsy-</i><br /><i>-Financial:</i><i>Vertex enters 2010 with approximately $1.3 billion
in cash, cash equivalents & marketable securities and approximately $32
million in outstanding convertible debt-</i><br />
<i>-VX-809 was well-tolerated at all dose levels when dosed once daily
for 28 days-</i>
<br />
<i>-Statistically significant changes observed in measurement of sweat
chloride suggest increased CFTR activity-</i>
<br />
<i>-Data support planned combination trial of VX-809 and VX-770 in
second half of 2010 for CF patients with the F508del mutation-</i>
<br />
<i>-HCV: New Drug Application planned for telaprevir in second half of
2010; increasing investment in commercialization and launch preparedness
activities-</i>
<br />
<i>-CF: Development progress with two compounds in orphan disease of
cystic fibrosis; combination trial planned with VX-770 and VX-809 based
on Phase 2 data for VX-809-</i>
<br />
<i>-Pipeline: Proof-of-concept clinical trials planned for 2010 with
novel combination regimens for hepatitis C and cystic fibrosis and with
compounds for rheumatoid arthritis and epilepsy-</i>
<br />
<i>-Financial: Vertex enters 2010 with approximately $1.3 billion in
cash, cash equivalents and marketable securities and approximately $32
million in outstanding 2013 convertible debt; 2010 investment to support
long-term business objectives-</i>
<br />
CAMBRIDGE, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 19, 2010 it will redeem the outstanding $32.1 million aggregate principal amount of 4.75% Convertible Senior Subordinated Notes due 2013, in accordance with the terms of the
<i>-Trial will evaluate safety and SVR rates with multiple 12-week
response-guided regimens of telaprevir/VX-222-based combination therapy,
including two-drug regimens of telaprevir and VX-222-</i>
<br />
<i>-Interim clinical data expected in the second half of 2010-</i>
<br />
<i>-Multiple clinical trial sites in the U.S. to enroll patients-</i>
<br />
CAMBRIDGE, Mass., Mar 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45 th
<i><b>-51% and 53% SVR rates when telaprevir was dosed in combination
with pegylated-interferon and ribavirin in treatment-failure patients,
compared to 14% SVR rate with pegylated-interferon and ribavirin alone-</b></i>
<br />
<i><b>-Telaprevir Phase 3 SVR data expected in second quarter 2010 for
treatment-naïve patients and third quarter 2010 for treatment-failure
patients-</b></i>
<br />
<i><b>-New Drug Application submission planned for second half of 2010
in treatment-naïve and treatment-failure HCV patients-</b></i>
<br />
<i>-56% of prior treatment null responder patients achieved SVR with a
48-week telaprevir-based regimen-</i>
<br />
<i>-97% of prior treatment relapsers and 55% of prior treatment partial
responders achieved SVR with 24-week or 48-week telaprevir-based
regimens-</i>
<br />
<i>-VX-222 was well-tolerated across all four dose groups through three
days of dosing, with all adverse events being mild to moderate in
severity-</i>
<br />
<i>-Greater than 3 log</i><sub><i>10 </i></sub><i>reduction in HCV RNA
observed across all four VX-222 dose groups-</i>
<br />
<i>-Results support previously announced Phase 2 proof-of-concept
clinical trial evaluating VX-222 in combination with Vertex's lead HCV
protease inhibitor telaprevir-</i>
<br />
<i>-HCV: Rolling submission of New Drug Application for telaprevir
expected to begin in summer of 2010; first Phase 3 SVR data expected in
second quarter 2010 from ADVANCE trial-</i>
<br />
<i>-CF: STRIVE, ENVISION and DISCOVER trials dosing patients as part of
Phase 3 registration program for VX-770; data expected in first half of
2011-</i>
<br />
<i>-Pipeline: Multiple ongoing or planned proof-of-concept clinical
trials with compounds for rheumatoid arthritis and epilepsy and with
novel combination regimens for HCV and CF-</i>
<br />
<i>-Financial: Vertex ends first quarter with cash position of
approximately $1.1 billion-</i>
<br />
